Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus Chemotherapy in Advanced Thymic Cancer (iTHYM)
NCT06750952Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ivonescimab in thymic carcinoma (TC), sponsored by Sun Yat-sen University. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT06750952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750952.